Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study) - Archive ouverte HAL Access content directly
Journal Articles European Respiratory Journal Year : 2021

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)

Sergio Muñiz-Castrillo
Bastien Joubert
  • Function : Author
Mad-Hélénie Elsensohn
  • Function : Author
Anne-Laurie Pinto
  • Function : Author
Margaux Saint-Martin
  • Function : Author
Alberto Vogrig
Géraldine Picard
  • Function : Author
Véronique Rogemond
  • Function : Author
Valérie Dubois
  • Function : Author
Ryad Tamouza
  • Function : Author
Jérôme Honnorat

Abstract

In patients with chronic fibrosing interstitial lung disease (ILD), a progressive fibrosing phenotype (PF-ILD) may develop, but information on the frequency and characteristics of this population outside clinical trials is lacking. We assessed the characteristics and outcomes of patients with PF-ILD other than idiopathic pulmonary fibrosis (IPF) in a real-world, single-centre clinical cohort. The files of all consecutive adult patients with fibrosing ILD (2010–2017) were examined retrospectively for pre-defined criteria of ≥10% fibrosis on high-resolution computed tomography and progressive disease during overlapping windows of 2 years. Baseline was defined as the date disease progression was identified. Patients receiving nintedanib or pirfenidone were censored from survival and progression analyses. In total, 1395 patients were screened; 617 had ILD other than IPF or combined pulmonary fibrosis and emphysema, and 168 had progressive fibrosing phenotypes. In 165 evaluable patients, median age was 61 years; 57% were female. Baseline mean forced vital capacity (FVC) was 74±22% predicted. Median duration of follow-up was 46.2 months. Annualised FVC decline during the first year was estimated at 136±328 mL using a linear mixed model. Overall survival was 83% at 3 years and 72% at 5 years. Using multivariate Cox regression analysis, mortality was significantly associated with relative FVC decline ≥10% in the previous 24 months (p<0.05), age ≥50 years (p<0.01) and diagnosis subgroup (p<0.01). In this cohort of patients with PF-ILD not receiving antifibrotic therapy, the disease followed a course characterised by continued decline in lung function, which predicted mortality.
No file

Dates and versions

hal-04151800 , version 1 (05-07-2023)

Identifiers

Cite

Sergio Muñiz-Castrillo, Bastien Joubert, Mad-Hélénie Elsensohn, Anne-Laurie Pinto, Margaux Saint-Martin, et al.. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). European Respiratory Journal, 2021, 57 (2), pp.2002718. ⟨10.1136/jnnp-2020-323226⟩. ⟨hal-04151800⟩

Collections

HCL ANR
2 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More